Summary Cytokinetic parameters of various types of lung cancer were determined in bronchoscopy specimens after in vivo labelling with the thymidine analogue bromodeoxyuridine (BrdU). The S-phase fraction and BrdU labelling index were measured flow cytometrically, allowing calculation of the S-phase transit time and potential tumour doubling time. The methodology used was found to be feasible for obtaining cytokinetic data from 76% of the bronchial biopsy samples.
Individual lung cancers differ in histological pattern and other phenotypic characteristics. These differences are relevant in predicting therapeutic responsiveness and prognosis (Fraire et al.,1992) . In recent years it has become evidence that in lung cancer as well as in other types of malignancy, cell cycle parameters may be important prognosticators (Tubiana & Courdi, 1989) . In several studies, a high S-phase fraction (SPF) was found to be associated with a shorter survival time (Ten Velde et al., 1988; Volm et al., 1985) ; this was also found for tumours other than lung carcinoma, including breast carcinoma (Kallioniemi et al., 1986; O'Reilly et al., 1990) . In addition, a low ex vivo thymidine labelling index in patients with stage I NSCLC predicts a longer survival time (Silvestrini et al., 1991) .
Ex vivo labelling assays, as used in some of the studies described above, are sensitive to technical variability since they rely on the ex vivo continuation of DNA synthetic activity and on an efficient incorporation of the label. Also, measurements of SPF and ex vivo labelling index (LI) do not allow the estimation of dynamic cytokinetic parameters such as the S-phase transit time (Ts) and the potential tumour doubling time (Tpot) .
A more accurate and comprehensive description of cytokinetic behaviour is possible by in vivo labelling of tumour cells with the thymidine analogue bromodeoxyuridine (BrdU) . If some time is allowed to elapse between pulse labelling and sampling, it is possible to determine cell kinetic properties over time from a single sample (Begg et al., 1985; Carlton et al., 1991) . In this study, the feasibility of this methodology in the cytokinetic analysis of bronchoscopy specimens is described. The first results indicate that cell loss may play a more significant role in determining the growth rate of lung tumours than has been assumed so far.
Materials and methods

Patient material
Patients selected for this study were 
Flow cytometry and BrdU detection
The biopsy specimens were double-stained with anti-BrdU (clone IIbS; Schutte et al., 1987) and propidium iodide (PI), using the protocol described by Schutte et al. (1987) . Briefly, ethanol fixed biopsies were minced in a petri dish and washed twice in phosphate buffered saline (PBS) pH 7.4, by centrifugation for 5 min at 400 g. To obtain nuclei, the cell suspension was digested with 0.4 mg ml-' pepsin (Boehringer Mannheim, Germany; 108057) in 0.1 N HCI for 30 min at room temperature. Undigested fragments were then removed by sieving through a 50 fim nylon mesh. After a washing step in PBS, the supernatant was removed and the pellet incubated in 2 ml 2 N HCI, for 30 min at 37°C. The nuclear suspension was then washed twice in Borax buffer (0.1 M sodiumtetraborate, pH 8.5), and once in PBS containing 0.1% bovine serum albumin (BSA) and 0.1% sodium azide (NaN3). The pelleted nuclei were resuspended in 100 All monoclonal anti-BrdU antibody, appropriately diluted in PBS/BSA/NaN3, and incubated for 60 min at room temperature followed by two washing steps in PBS/BSA/ NaN3. Primary antibody binding was visualised by incubating the pellet with 100 flI 1:20 diluted FITC conjugated Fab2 fragments of rabbit anti-mouse IgG (DAKO-PATTS, Glostrup, Denmark; F3 13) for 60 min at room temperature in the dark. After washing twice in PBS/BSA/ NaN3, the nuclei were finally.counterstained with 0.5 ml of a 10 lOg ml-' propidium iodide (Calbiochem, La Jolla, CA; 537059) solution in PBS containing 0.1 mg ml-' RNase (Serva, Heidelberg, Germany). After incubation for at least 15min in the dark, the samples were analysed using the FACS IV flow cytometer (Becton & Dickinson, Sunnyvale, CA, USA). A total number of 5000 nuclei per sample were recorded.
Calculation of cytokinetic parameters The DNA index (DI) was estimated from the single paramater DNA histograms. In case of one GI peak the sample was defined as diploid and the DNA index was considered 1.0; in case of two GI peaks the sample was defined as aneuploid and the DNA index was calculated by dividing the channel number of the right-sided peak to the channel number of the left-sided one, according to Hiddeman et al. (1984) . The S-phase fraction (SPF) was determined from the DNA histogram using the rectangular fit method described by Baisch et al. (1982) . To calculate the S-phase transit time (Ts), the relative movement (RM) of the labelled cells during the BrdU chase time t (=the time passed between administration of the BrdU pulse and fixation after bronchoscopy) was measured according to Begg et al. (1985) .
In formula, the relative movement is defined by: (Table I) .
Ploidy characteristics are given in Table II . Of all biopsies that contained malignant cells (n = 32), 38% appeared to contain an aneuploid stemline; the median relative size of the We next compared the cytokinetic characteristics for diploid and aneuploid tumours and included also the group of lung cancer patients with non-malignant, diploid biopsies (Table IV) . The potential doubling time appears to decrease in the order of non-malignant tissue, diploid tumours and aneuploid tumours. This occurred despite the fact that aneuploid tumours had a longer S-phase transit time and therefore can only be explained by their high labelling index.
In all samples the SPF appeared to exceed the LI to a considerable extent. We therefore investigated whether these two potential parameters of S-phase activity are indeed interrelated. In Figure 1 the correlation between LI and SPF is given for all samples with full analysis (n = 38). The two parameters correlated significantly (r = 0.77), but at the level of individual samples the SPF almost always exceeded the LI. This suggests the presence of a considerable number of cells with S-phase DNA content without the ability to incorporate BrdU; we called these cells 'unlabelled S-phase cells'. The presence of unlabelled S-phase cells could be a tumour characteristic with prognostic or therapeutic implications. An example of the presence of a considerable population of cells with S-phase DNA content but without incorporated BrdU is given in Figure 2 . We developed methodologies to quantify their frequency by determining an 'unlabelled S-phase fraction' or USPF, indicating the fraction of all cells with Sphase DNA content that do not label. This was done using the following formula: USPF = (SPF-LI)/SPF. This formula was applied to the population at large (method 1) or to a representative portion of the population by restricting the analysis to a small segment in the second part of the S-phase (method 2). The latter method avoids the possible disturbing effect of cells that are unlabelled because they entered the S-phase in the time period between in vivo labelling and bronchoscopy.
Results of the two methods are given in Table III . It appears that the two methods to estimate the USPF are different in that method 2 gives higher estimates. However, in the 3 groups of patients the results of the two methods show a similar tendency; the correlation coefficient was found to be 0.7 (P = 5.9E-5). Whatever method used, the USPF appears to be lower in malignant samples (P = 0.01 (method 1) or P = 0.0064 (method 2)).
Discussion
The main goal of this study was to investigate the feasibility of determining cytokinetic characteristics from human bronchoscopy specimens. Therefore we entered a heterogeneous group of patients encompassing the full spectrum of types and stages of bronchial carcinoma as well as biopsies of normal bronchial tissue. Fifty of such specimens were adequate to the extent that patients were eligible and a nuclear suspension of good enough quality for flow cytometric analysis was obtained. Full analysis was possible in 76% of all cases. The main reasons for not being able to perform cytokinetic analysis was the failure to detect a coherent cohort of labelled cells. In these samples very few cells (less than 1%) were found labelled with BrdU and these cells were randomly scattered over the dotplot. This occurred in 6/17 non-malignant and in 6/33 malignant specimens, indicating that successful analysis is possible in an even higher percentage of patients with malignant tumours. Acute side-effects were not observed with the dose of BrdU employed, as has also been the case in earlier studies with this dose and slightly higher doses (Forster et al., 1992; Hoshino et al., 1985; Hupperets et al., 1986; Miller et al., 1991; Nagashima et al., 1988; Shimomatsuya et al., 1991; Ten Velde et al., 1989a; Wilson et al., 1988) .
During the course of this study, some problems have arisen concerning flow cytometric analysis. Difficulties in discerning the tumour cell population from other cell types present in the bronchoscopy sample were manifest in particular in diploid samples, where it is not possible to make a distinction between normal cells or tumour cells with a diploid DNA content. In aneuploid samples, the major problem was overlap of diploid and aneuploid populations. An additional disturbing effect was generated by the accumulation of cell debris in the sample. This makes estimations of cell numbers in various phases of the cell cycle less reliable. In order to avoid the problems mentioned above, we started to investigate the use of dual parameter image cytometry as an alternative. This technique is currently being optimised. Begg et al. (1991) recently described three-colour fluorescence flow cytometry as a method for selecting the desired malignant cell population for kinetic analysis, that also may be useful in this respect.
One of the most striking results of this study is the finding of a considerable number of cells with a DNA content between GI and G2 that do not take up BrdU: the so-called unlabelled S-phase cells. These cells were observed in virtually each sample. Previously, the existence of this phenomenon had also been described by Darzynkiewicz (1986) , Forster et al. (1992) , Ten Velde et al. (1989a and b) and Wilson et al. (1988) , while an exceeding of the SPF over the LI was reported by Meyer & Coplin (1988); Teodori et al. (1990) and Wilson et al. (1985) . We were concerned about technical artefacts and therefore determined the frequency of such cells (USPF) by restricting the analysis to a window close to the G2/M peak. This eliminates the contribution of cells that have entered the S-phase in the time between labelling with BrdU and sampling of the biopsy, and would also possibly decrease the influence of debris. Still, we found that 36-99% of the S-phase cells were unlabelled. In inter- preting these data it has to be taken into account, however, that cell debris may still interfere with the estimation of the USPF, in particular in diploid samples with a relatively low frequency of labelled cells. This is due to the fact that cell debris shows an exponential decline with relatively higher counts in the lower DNA channels. This may in part explain why normal tissues with a low LI were found to have a higher USPF as compared to malignant biopsies. A second possibility to explain the presence of unlabelled S-phase cells could be that cells, for some reason, stop cycling during S-phase. Assuming that this is a random event, this would imply that cells in the BrdU labelled population will arrest also. According to the theoretical model developed by White (1991) , this will result in high values for Ts. Therefore, the length of the S-phase transit time could be another indicator for the presence of unlabelled S-phase cells. From the data presented in Table III than in small cell lung cancer. The mean tumour volume doubling times for these types of lung cancer are approximately 3 months (100 days) for NSCLC and 1 month (30 days) for SCLC (Selawry & Hansen, 1982) . Our cytokinetic data however, indicate a doubling of the cell number in 8.1 days (NSCLC) and 8.6 days (SCLC). Wilson et al. (1988) , who calculated the potential tumour doubling time in 25 solid human tumours, found an overall mean of only 5.5 days. A significant discrepancy between the calculated tumour doubling time and the measured doubling time was also reported by Terz et al. (1971) . The cell loss factor can be defined as (1-(Tp0,/Td)) x 100% (Steel, 1977) , where Tpot is the potential doubling time (assuming there is no cell loss) and Td is the actual doubling time. Using this formula and our data, the cell loss factor in NSCLC is estimated as to be 90%, whereas the cell loss in SCLC is estimated on 70%. This is in accord with one previous report, in which the cell loss of human tumours was found to range from 40% to 80%, with a higher cell loss in squamous cell lung carcinoma than in small cell lung carcinoma (Shimomatsuya et al., 1991) . Taken together, our data strongly support the concept that the relatively slow growth rate of NSCLC as compared to SCLC does not depend on differences in proliferation but rather on the rate of cell loss.
Reports in the literature, concerning Ki67 expression, show no significant differences between SCLC and NSCLC, although there seems to be a trend-towards a higher positive Ki67 fraction in SCLC (Gatter et al., 1986 , Soomroo & Whimster, 1990 ). This is not in conflict with our hypothesis that SCLC exhibit a lower cell loss factor than NSCLC, since Ki67 is a protein which is expressed in proliferating cells. However, it is a static marker which does not reflect active proliferation and which therefore cannot be directly compared to the cytokinetic parameters measured in this study.
We have demonstrated the feasibility of obtaining dynamic cytokinetic data from bronchoscopy specimens after in vivo labelling with BrdU in a majority of patients presenting with lung cancer. Growth parameters such as the potential tumour doubling time, the S-phase transit time and an estimation of the presence of arrested S-phase cells can be obtained that will now be assessed for their prognostic and therapeutic implications.
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